Market Access/ Views & Analysis/ Views and analysis An alternative set of metrics for the UK’s pricing and access deal Leela Barham HTA, NICE, pricing, UK, VPAS 0 Comment Leela Barham takes a look at alternative ways pharma and the UK government could measure progress for the Share X An alternative set of metrics for the UK’s pricing and access deal https://pharmaphorum.com/views-and-analysis/an-alternative-set-of-metrics-for-the-uks-pricing-and-access-deal/
Market Access/ Sales and Marketing/ Views & Analysis/ Views & Analysis/ Views and analysis VPAS 2024: What should industry consider next time? Leela Barham government, NHS, pricing, UK, VPAS 0 Comment The UK pharmaceutical industry is just getting to grips with working under two new approaches to regulating branded Share X VPAS 2024: What should industry consider next time? https://pharmaphorum.com/views-analysis-market-access/vpas-2024-what-should-industry-consider-next-time/
